Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0)

NCT01091168 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT01091168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01091168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0)
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2009
Completion date
January 31, 2014
Enrollment
594 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastases